iBio Announces Appointment of Dr. Alexandra Kropotova to Board of Directors
15 Octobre 2020 - 1:30PM
iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech
innovator and biologics contract manufacturing organization, today
announced the appointment of Dr. Alexandra Kropotova to its Board
of Directors, effective as of October 14, 2020. Dr. Kropotova has
also been appointed as a member of iBio’s new Science &
Technology Committee, which shall be chaired by Dr. Philip Russell.
Dr. Kropotova is a biopharmaceutical executive
with expertise in all phases of global clinical development,
translational medicine and medical affairs. Since 2016, she has
served as Vice President, Global Specialty R&D, Respiratory
& Inflammation Therapeutic Area at Teva Pharmaceuticals
(TASE:TEVA), where she leads the design and execution of global
clinical development programs, the majority of which are biologic
candidates for pulmonary, chronic inflammatory or autoimmune
indications.
Prior to joining Teva, Dr. Kropotova served in
various roles at Sanofi (EPA:SAN), including Vice President,
Strategy & Strategic Planning Head, North American Medical
Affairs; Associate Vice President and subsequently Vice President,
Immuno-Inflammation, Global R&D; and Senior Medical Director,
Respiratory, Allergy & Anti-Infectives. Prior to joining
Sanofi, she served in various roles at Pfizer Inc., most recently
as Director & Head of Global Clinical Respiratory and
Analgesics. Dr. Kropotova received her Master of Business
Administration Degree from Ohio University Graduate School of
Business, Athens, Ohio; and her Medical Degree in Internal Medicine
from the Vladivostok State Medical University, Vladivostok,
Russia.
“We are pleased to welcome Dr. Kropotova to our
Board and value her vast biologics development experience across
multiple therapeutic areas,” said Tom Isett, Chairman & CEO of
iBio. “Her strategic portfolio planning insights should be an
invaluable asset to iBio’s Science & Technology Committee as we
continue to expand our biopharmaceutical development activities in
pulmonology, oncology, and fibrotic diseases.”
Dr. Kropotova commented, “I am greatly honored
by the vote of confidence. I have the commitment to work tirelessly
with the iBio Board, bringing my diverse background and passion to
make smart decisions in strategic planning and be street-wise in
our actions."
About iBio, Inc.
iBio is a global leader in plant-based biologics
manufacturing. Its FastPharming®
System combines vertical farming, automated hydroponics, and glycan
engineering technologies to rapidly deliver high-quality monoclonal
antibodies, vaccines, bioinks and other proteins. The Company’s
subsidiary, iBio CDMO LLC, provides FastPharming
Contract Development and Manufacturing Services. iBio’s
Glycaneering Development Service™
includes an array of new glycosylation technologies for engineering
high-performance recombinant proteins. Additionally, iBio is
developing proprietary products, which include IBIO-100 for the
treatment of fibrotic diseases, and vaccines for COVID-19 disease.
For more information, visit www.ibioinc.com.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release
constitute "forward-looking statements" within the meaning of the
federal securities laws. Words such as "may," "might," "will,"
"should," "believe," "expect," "anticipate," "estimate,"
"continue," "predict," "forecast," "project," "plan," "intend" or
similar expressions, or statements regarding intent, belief, or
current expectations, are forward-looking statements. These
forward-looking statements are based upon current estimates and
assumptions and include statements regarding the expected
contribution of Dr. Kropotova. While the Company believes these
forward-looking statements are reasonable, undue reliance should
not be placed on any such forward-looking statements, which are
based on information available to us on the date of this release.
These forward-looking statements are subject to various risks and
uncertainties, many of which are difficult to predict that could
cause actual results to differ materially from current expectations
and assumptions from those set forth or implied by any
forward-looking statements. Important factors that could cause
actual results to differ materially from current expectations
include, among others, the contribution of Dr. Kropotova to the
Board and to iBio’s Science & Technology Committee, the
Company’s ability to obtain regulatory approvals for
commercialization of its product candidates, including its COVID-19
vaccines, or to comply with ongoing regulatory requirements,
regulatory limitations relating to its ability to promote or
commercialize its product candidates for specific indications,
acceptance of its product candidates in the marketplace and the
successful development, marketing or sale of products, its ability
to maintain its license agreements, the continued maintenance and
growth of its patent estate, its ability to establish and maintain
collaborations, its ability to obtain or maintain the capital or
grants necessary to fund its research and development activities,
competition, its ability to retain its key employees or maintain
its NYSE American listing, and the other factors discussed in the
Company’s Annual Report on Form 10-K for the year ended June 30,
2020 and the Company’s subsequent filings with the SEC, including
subsequent periodic reports on Forms 10-Q and 8-K. The information
in this release is provided only as of the date of this release,
and we undertake no obligation to update any forward-looking
statements contained in this release on account of new information,
future events, or otherwise, except as required by law.
Contact:
Stephen KilmeriBio, Inc.Investor Relations(646)
274-3580 skilmer@ibioinc.com
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Août 2023 à Août 2024